Mycophenolate mofetil
- PDF / 141,274 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 57 Downloads / 187 Views
1
S
Various toxicities: 9 case reports Nine women, aged 22–55 years, were identified from a retrospective study after they developed various toxicities while receiving mycophenolate mofetil for cutaneous lupus erythematosus [routes, durations of treatment to reaction onset and outcomes not stated]. The women all commenced mycophenolate mofetil 500 mg/day, with a subsequent dosage increase to 2500–3500 mg/day. Three women developed adverse effects that contributed to discontinuation of mycophenolate mofetil; either a hypersensitivity rash, increased liver enzyme levels, or diarrhoea at dosages above 2000 mg/day. Two women developed recurrent herpes simplex virus infections, with one of these also experiencing GI upset at dosages above 2000 mg/day, while a third woman had herpes zoster and lupus nephritis. Mycophenolate mofetil therapy was continued in these three cases. The remaining three women developed either leucopenia, methicillin-resistant Staphylococcus aureus furunculosis and candidiasis, or abdominal pain and nausea. Gammon B, et al. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. Journal of the American Academy of Dermatology 65: 717-721.e2, No. 4, Oct 2011. Available from: URL: http://dx.doi.org/10.1016/ 803062611 j.jaad.2010.08.011 - USA
0114-9954/10/1377-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 12 Nov 2011 No. 1377
Data Loading...
